2 ‘under the radar’ growth stocks I’d consider buying today

Bilaal Mohamed discovers two ‘hidden gems’ from among the smaller London-listed companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Sinclair Pharma (LSE: SPH) this morning announced its interim results for 2017, reporting a 16% rise in group revenues after particularly strong demand in Brazil for its aesthetic dermatology products.

Emerging markets

The AIM-listed group specialises in providing aesthetic dermatology solutions through collagen stimulation for facial volume loss, thread lifting for facial contouring and dermal fillers for wrinkles and lines. The company has an established sales and marketing footprint in the UK, France, Germany, Italy and Spain, as well as a rapidly-growing presence in emerging markets around the world.

For the six months to 30 June, revenues reached £20.1m, compared to £17.3m for the first half of 2016, with gross profit up 19% to £14.5m, together with a strong improvement in gross margin from 70.5% to 72.4%. Sales were bolstered by strong demand in Brazil, with the South American country becoming an increasingly important market for the group.

Facelift

In recent years, there has been growing demand for plastic surgery and other aesthetic treatments from the country’s rapidly-growing middle class population. Indeed, Sinclair’s Brazilian affiliate, created in July 2016, has already become the group’s largest direct operation in terms of sales.

I think a combination of vanity and an ageing population should help to drive growth both in Europe and worldwide long into the future. So right now, I feel that Sinclair Pharma could be the perfect stock to give your portfolio a much-needed facelift.

LED technology

Another London-listed small-cap worthy of a closer look at the moment is LED lighting specialist Luceco (LSE: LUCE). The £380m firm is a rapidly growing manufacturer and distributor of high quality and innovative LED lighting products and wiring accessories for a global customer base.

The Luceco LED lighting brand continues to benefit from the shift away from old-fashioned lighting technologies as a result of recent advancements in LED technology. The brand has continued to successfully leverage the group’s existing customer base and low-cost Chinese manufacturing facility, and remains well positioned to build on an already-impressive record of organic growth.

Meanwhile, in the electrical wiring accessories market, Luceco’s BG and Masterplug brands have continued to reinforce their market-leading positions through further new product development initiatives, expanding into new products and gaining market share.

Chinese expansion

Luceco operates a fully-integrated operating model which includes wholly-owned manufacturing and product development facilities in the UK and China that enables it to maintain strong control over its cost base and the quality of its products, while allowing it to bring products to market quickly and at low cost.

The business is also well positioned for future growth with recent investment made in the expansion of its Chinese manufacturing facility and sales network, both in the UK and internationally, to support the group’s existing and new product ranges.

Luceco’s shares have performed well since last October’s Stock Market debut, soaring from their IPO price of 130p to today’s levels around 237p, and I’ve no doubt they’ll continue to outperform. With double-digit earnings growth forecast for the next couple of years, I believe today’s valuation at 23 times forward earnings is still not too demanding given the promise of further expansion.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has recommended Luceco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »